At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 230 enrolled
Drug / intervention
Nivolumab +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Exploratory Study of the Biologic Effects and Biomarkers of Nivolumab in Combination With Ipilimumab in Subjects With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
In Brief
A Phase 2 clinical trial evaluating Nivolumab and Ipilimumab for Non-Small Cell Lung Cancer. Completed, enrolled 230 participants across 35 sites in 8 countries.
Detailed Summary
The purpose of this study is to explore the possible links between participant characteristics and their cancer, with how effective the combination of nivolumab with ipilimumab is, in participants with Stage IV or recurrent Non-Small Cell Lung Cancer (NSCLC).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Small Cell Lung Cancer
CountriesBelgium, France, Germany, Italy, Netherlands, Romania, Spain, United States
CollaboratorsYale University
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedDec 2016
Enrollment StartMar 2017
Primary CompletionFeb 2022
Study CompletionApr 2023
TodayJul 2026
First PostedDec 23, 2016
Enrollment StartMar 29, 2017
Primary CompletionFeb 17, 2022
Study CompletionApr 24, 2023
TodayJul 2, 2026
Enrollment to primary: 4.9 yearsPosted 9.5 years ago
Interventions
Nivolumabbiological
Specified dose on specified days
Ipilimumabbiological
Specified dose on specified days